DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,641,186 | -13.5% | 127,534 | -16.4% | 0.09% | -6.2% |
| Q2 2023 | $36,590,879 | -77.6% | 152,462 | -76.5% | 0.10% | -79.2% |
| Q1 2023 | $163,559,594 | -19.8% | 648,943 | -15.5% | 0.47% | -25.7% |
| Q4 2022 | $203,865,660 | -33.9% | 768,087 | -35.7% | 0.63% | -30.1% |
| Q3 2022 | $308,447,000 | -11.6% | 1,194,187 | -13.2% | 0.90% | -6.7% |
| Q2 2022 | $348,982,000 | +47.0% | 1,376,545 | +70.1% | 0.96% | +73.2% |
| Q1 2022 | $237,388,000 | +41.3% | 809,286 | +58.5% | 0.56% | +52.9% |
| Q4 2021 | $167,959,000 | +6.2% | 510,499 | -1.7% | 0.36% | +7.7% |
| Q3 2021 | $158,095,000 | +45.2% | 519,299 | +28.0% | 0.34% | +43.4% |
| Q2 2021 | $108,900,000 | +21.8% | 405,799 | +2.1% | 0.24% | +16.3% |
| Q1 2021 | $89,419,000 | -38.3% | 397,276 | -39.1% | 0.20% | -39.7% |
| Q4 2020 | $144,901,000 | -12.7% | 652,296 | -15.4% | 0.34% | -24.2% |
| Q3 2020 | $165,936,000 | +6.6% | 770,613 | -12.4% | 0.44% | +0.9% |
| Q2 2020 | $155,630,000 | +40.4% | 880,113 | +9.9% | 0.44% | +25.1% |
| Q1 2020 | $110,854,000 | -36.8% | 800,913 | -30.0% | 0.35% | -18.0% |
| Q4 2019 | $175,506,000 | -2.8% | 1,143,513 | -8.5% | 0.43% | -3.0% |
| Q3 2019 | $180,496,000 | +4.4% | 1,249,713 | +3.3% | 0.44% | +2.3% |
| Q2 2019 | $172,821,000 | -19.4% | 1,209,213 | -25.5% | 0.43% | -21.0% |
| Q1 2019 | $214,297,000 | +12.0% | 1,623,213 | -12.5% | 0.54% | +4.0% |
| Q4 2018 | $191,351,000 | -5.4% | 1,855,613 | -0.3% | 0.52% | +11.5% |
| Q3 2018 | $202,185,000 | +9.7% | 1,860,713 | -0.4% | 0.47% | +7.3% |
| Q2 2018 | $184,266,000 | -0.2% | 1,867,313 | -1.0% | 0.44% | -2.2% |
| Q1 2018 | $184,699,000 | -5.8% | 1,886,413 | -10.7% | 0.45% | -1.3% |
| Q4 2017 | $195,981,000 | +6.0% | 2,111,413 | -1.6% | 0.45% | +6.3% |
| Q3 2017 | $184,816,000 | +8.7% | 2,145,513 | +6.2% | 0.43% | +2.9% |
| Q2 2017 | $170,011,000 | +23.8% | 2,020,213 | +25.9% | 0.41% | +21.1% |
| Q1 2017 | $137,366,000 | +11.3% | 1,604,313 | +1.1% | 0.34% | +9.6% |
| Q4 2016 | $123,366,000 | +29.0% | 1,586,813 | +30.0% | 0.31% | +31.1% |
| Q3 2016 | $95,668,000 | -7.9% | 1,220,413 | +18.6% | 0.24% | -10.9% |
| Q2 2016 | $103,910,000 | -1.4% | 1,028,813 | -7.4% | 0.27% | -5.7% |
| Q1 2016 | $105,343,000 | +36.0% | 1,110,513 | +33.1% | 0.28% | +32.2% |
| Q4 2015 | $77,480,000 | -36.1% | 834,200 | -41.4% | 0.21% | -35.9% |
| Q3 2015 | $121,245,000 | +22.6% | 1,422,900 | +23.2% | 0.33% | +28.0% |
| Q2 2015 | $98,891,000 | +5.8% | 1,155,400 | +4.9% | 0.26% | +0.4% |
| Q1 2015 | $93,500,000 | -14.8% | 1,101,300 | -14.0% | 0.26% | -10.7% |
| Q4 2014 | $109,777,000 | -1.1% | 1,280,800 | -12.3% | 0.29% | -3.3% |
| Q3 2014 | $110,961,000 | +19.3% | 1,460,400 | +23.6% | 0.30% | +18.0% |
| Q2 2014 | $93,002,000 | +6.3% | 1,181,280 | +1.2% | 0.26% | -3.0% |
| Q1 2014 | $87,510,000 | -5.5% | 1,166,800 | -2.7% | 0.26% | -6.4% |
| Q4 2013 | $92,565,000 | +4.4% | 1,199,030 | -6.3% | 0.28% | +11.5% |
| Q3 2013 | $88,674,000 | -4.9% | 1,279,200 | -13.1% | 0.25% | -6.7% |
| Q2 2013 | $93,228,000 | – | 1,472,800 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |